Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study

Author:

Oleichik I. V.ORCID,Baranov P. A.ORCID,Shishkovskaia T. I.ORCID

Abstract

Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identified as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efficacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efficacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efficacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efficacy in augmentation of antidepressant therapy and has a favorable tolerability profile. The maximum efficacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.

Publisher

Medical Informational Agency Publishers

Subject

Biological Psychiatry,Psychiatry and Mental health,Clinical Psychology

Reference63 articles.

1. Taneja C, Papakostas GI, Jing Y, Baker RA, ForbesRA, Oster G. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother. 2012;46(5):642–649. doi: 10.1345/aph.1Q326 Epub 2012 May 1. PMID: 22550279.

2. Goodwin GM, Abbar M, Schlaepfer TE, Grunze H, Licht RW, Bellivier F, Fountoulakis KN, Altamura AC, Pitchot W, Ågren H, Holsboer-Trachsler E, Vieta E. Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Curr Med Res Opin. 2011;27(12):2285–2299. doi: 10.1185/03007995.2011.628380

3. Seshadri A, Wermers ME, Habermann TJ, Singh B. Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis. Prim Care Companion CNS Disord. 2021;23(4):20r02799. doi: 10.4088/PCC.20r02799. PMID: 34167174.

4. Shin C, Pae CU, Kwak KP, Jeon SW, Jeong HG, Kim JW, Lee YJ, Patkar AA, Han C. Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2021;19(2):243–253. doi:10.9758/cpn.2021.19.2.243 PMID: 33888653; PMCID: PMC8077065.

5. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K, ADMIRE Study Group. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter. Psychiatry Clin Neurosci. 2015;69(1):34–42. doi: 10.1111/pcn.12214

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3